Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
Company profile
Ticker
NVO, NSRPF
Exchange
Website
CEO
Lars Fruergaard Jørgensen
Employees
Incorporated
Location
Fiscal year end
SEC CIK
NVO stock data
Latest filings (excl ownership)
D
$13.91M in equity / options / securities to be acquired, sold $1.3M, 2 investors
18 May 21
D/A
$34.35M in equity / options / securities to be acquired, sold $5.54M, 24 investors
22 Sep 20
D
$34.35M in equity / options / securities to be acquired, sold $5.54M, 24 investors
11 Sep 20
D
$3.21M in equity / options, sold $3.21M, 8 investors
11 May 17
D
$1.16M in equity / options, sold $1.16M, 15 investors
26 Aug 16
D
$442.87K in other securities, sold $442.87K, 1 investor
23 Mar 16
D
$499.12K in equity / options, sold $499.12K, 4 investors
23 Mar 16
D/A
$539.38K in equity / options / securities to be acquired, sold $212.48K, 3 investors
31 Jul 15
D
$285.49K in equity / options / securities to be acquired, sold $112.47K, 2 investors
13 Jul 15
D
$346.05K in equity / options / securities to be acquired, sold $145.12K, 2 investors
20 Dec 12
Latest ownership filings
No filings